Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of EndoTAG-1 plus gemcitabine versus gemcitabine alone after FOLFIRINOX failure in advanced pancreatic adenocarcinoma
MOH_2018-05-24_002374Phase 3Not yet recruiting
- Sponsor
- SynCore Biotechnology
- Start
- May 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing EndoTAG-1 plus gemcitabine with Gemcitabine monotherapy (2 arms). Planned start May 2018; status: not yet recruiting.
02
Drugs
EndoTAG-1gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2018-05-24_002374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-24_002374.